Does State Medicaid Cover Jatenzo?

What Is Jatenzo and Why Does Coverage Matter?

Jatenzo is the first FDA-approved oral testosterone replacement therapy for adult men with hypogonadism caused by certain medical conditions. The drug's $900 monthly list price makes Medicaid coverage binary: patients either get it at near-zero cost or face a prescription they cannot fill. Unlike generic injectable testosterone cypionate, which costs as little as $30 per month at most pharmacies, Jatenzo carries a premium that Medicaid programs scrutinize closely before adding it to formulary.

The FDA approved Jatenzo in March 2019 specifically for adult males with primary hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired). The label explicitly excludes use in men with age-related low testosterone absent an underlying medical condition, a restriction that Medicaid programs repeat almost verbatim in their coverage criteria. The FDA prescribing information for Jatenzo outlines a specific dose-titration protocol: 237 mg twice daily with a fat-containing meal, adjustable at week 3 to 158 mg or 316 mg twice daily based on serum testosterone drawn 3 to 5 hours post-dose.

The key registration trial by Swerdloff et al. (2020, N=166) found that 87% of treated men achieved at least one testosterone value in the normal range (300 to 1 to 000 ng/dL), with a mean steady-state Cavg of 498 ng/dL [1]. That trial data, published in the Journal of Clinical Endocrinology and Metabolism, is the backbone clinicians use when writing letters of medical necessity for Medicaid appeals. Payers who deny coverage cannot easily dismiss a Phase 3 dataset showing near-nine-in-ten responders hitting therapeutic targets.

Hypogonadism affects an estimated 2.1% to 3.8% of adult men in the United States, with prevalence rising in men over 45 [2]. The Endocrine Society's 2018 clinical practice guideline defines biochemical hypogonadism as a consistently low morning total testosterone, typically <300 ng/dL on two separate measurements, combined with symptoms [3]. Meeting that clinical threshold is the first and most consistently required criterion across every state Medicaid program that covers Jatenzo at all.

How State Medicaid Formularies Work for Testosterone Products

Each state Medicaid program maintains a preferred drug list (PDL) that assigns drugs to tiers or marks them as non-preferred or non-covered. The Centers for Medicare and Medicaid Services (CMS) sets baseline rules but grants states broad latitude over which drugs appear on the PDL and what utilization management tools are attached.

For testosterone replacement products, states generally organize coverage into three tiers: generic injectables (testosterone cypionate, testosterone enanthate) at the lowest cost-sharing tier; brand topicals (AndroGel, Testim) at a mid-tier often requiring prior authorization; and oral agents like Jatenzo at a high or non-preferred tier requiring prior authorization plus documented failure of a lower-tier agent.

The CMS Medicaid Drug Rebate Program (MDRP) requires manufacturers to pay rebates on covered outpatient drugs, which reduces the net cost to state programs [4]. Novo Nordisk and AbbVie negotiate rebates; Clarus Therapeutics (Jatenzo's manufacturer, now part of Halozyme's portfolio) must do the same. States that have not executed a supplemental rebate agreement for Jatenzo may place it in a non-preferred position simply because the net cost exceeds covered alternatives, not because of clinical inferiority.

The practical result: a man with documented primary hypogonadism in California may get Jatenzo approved on the first prior authorization attempt, while an identical clinical profile in a neighboring state results in automatic denial pending step therapy through two injectable formulations. Checking your state's specific PDL at the state Medicaid agency website is the only reliable starting point before prescribing or appealing.

Prior Authorization Criteria Across State Medicaid Programs

Prior authorization for Jatenzo on Medicaid almost universally requires the same core documentation, though the exact thresholds differ by state.

The minimum documentation package that satisfies PA criteria in states that cover Jatenzo includes: two morning fasting serum testosterone measurements below the state-specified threshold (most commonly <300 ng/dL, measured on separate days at least one week apart); a confirmed diagnosis of primary or hypogonadotropic hypogonadism consistent with the FDA-approved indication; documented clinical symptoms (decreased libido, fatigue, reduced muscle mass, or mood disturbance); confirmation that the patient is an adult male; and prescriber attestation that the patient has no contraindications listed in the Jatenzo label (prostate cancer, male breast cancer, known hypersensitivity) [5].

Several states add a prescriber-specialty requirement, limiting initial PA approval to endocrinologists or urologists. A primary care physician prescribing Jatenzo in those states may receive an automatic technical denial regardless of clinical documentation quality. The Endocrine Society's 2018 testosterone therapy guideline states: "We suggest measuring morning total testosterone levels on 2 separate occasions in men suspected of having androgen deficiency." That sentence, verbatim, appears in the coverage criteria language of at least a dozen state PDL documents.

The HealthRX clinical team has identified a four-component PA submission framework that addresses the most common denial reasons across state Medicaid programs:

1. Lab documentation: Two testosterone levels with exact collection times noted (7 a.m. to 10 a.m.), both <300 ng/dL, drawn at least one week apart with no acute illness, recent opioid use, or glucocorticoid use that could suppress levels.
2. Diagnosis confirmation: LH and FSH values distinguishing primary from secondary hypogonadism, with etiology documented (prior orchiectomy, Klinefelter syndrome, pituitary tumor, etc.) when applicable.
3. Symptom burden: A completed Aging Males' Symptoms (AMS) scale or ADAM questionnaire score in the medical record, not just a narrative note.
4. Oral-route justification: A specific clinical reason why injectable testosterone is not appropriate (needle phobia with documented avoidance behavior, bleeding disorder, occupational exposure restriction, or prior injection-site complications documented in the chart).

Without the fourth component, Medicaid reviewers in step-therapy states have little reason to approve the oral agent over a far cheaper injectable. The American Urological Association's 2018 testosterone deficiency guideline supports route selection based on patient preference and clinical circumstances, which gives prescribers a guideline-level anchor for that justification [6].

Step Therapy Requirements: What States Demand Before Jatenzo

Step therapy means a patient must try and fail a lower-cost agent before the insurer will cover the requested drug. For Jatenzo, most step-therapy states require documented failure of at least one injectable testosterone product, typically testosterone cypionate 200 mg/mL injection.

"Failure" in this context is defined narrowly by payers and broadly by clinicians. Payers prefer documented treatment failure as inadequate testosterone normalization (testosterone remaining <300 ng/dL after adequate dose and duration). Clinicians more often invoke adverse effects, adherence barriers, or route intolerability as failure criteria. Medicaid reviewers routinely reject adverse-effect claims unless the chart contains contemporaneous documentation of the reaction, not a retrospective patient report written at the time of the Jatenzo PA request.

A 2019 analysis of testosterone formulation adherence found that injectable testosterone had 12-month continuation rates of approximately 68%, compared to topical gel at 54%, suggesting real-world tolerability differences that can anchor step-therapy failure arguments [7]. If a patient genuinely cannot or will not self-inject, documenting that in the initial visit (before any PA is submitted) is far more persuasive than a letter written after denial.

Some states have enacted step-therapy transparency laws requiring payers to grant exceptions when step therapy is contraindicated, clinically inappropriate, or when the patient previously failed the required therapy on a different plan. As of 2024, at least 32 states had enacted such laws covering Medicaid managed care plans, though enforcement varies and state-only fee-for-service Medicaid is sometimes exempt [8]. Knowing whether your state's law covers the specific Medicaid subtype (managed care organization vs. fee-for-service) is critical before filing an exception request.

How to Appeal a Jatenzo Denial From State Medicaid

A Medicaid denial for Jatenzo is not final. Federal law requires state Medicaid programs to provide a fair hearing within 90 days of a beneficiary's appeal request, under 42 CFR Section 431.244.

The appeal process has two sequential tracks. The first is an internal reconsideration or peer-to-peer review: the prescribing physician speaks directly with the Medicaid medical reviewer, presents clinical documentation, and argues for coverage. Peer-to-peer calls succeed in a substantial minority of cases and cost nothing but time. Request this call within the payer's stated window (usually 5 to 14 business days from denial notice).

If internal reconsideration fails, the patient has the right to request a state fair hearing. The CMS Medicaid Beneficiary Appeals guidance specifies that beneficiaries must receive written notice of denial with the specific reason cited, the right to appeal, and the deadline for doing so [9]. That written denial notice is the starting document for every appeal. File the fair-hearing request before the deadline printed on the denial letter (commonly 30 to 90 days depending on state).

A strong fair-hearing packet includes: the original denial letter; a prescriber letter of medical necessity citing the Swerdloff et al. (2020) Phase 3 trial data [1], the Endocrine Society guideline recommendation for testosterone therapy in men with symptomatic hypogonadism [3], and the AUA testosterone deficiency guideline [6]; complete lab documentation as described above; and any published peer-reviewed evidence that oral testosterone offers clinically meaningful advantages in the patient's specific situation. A 2021 review in Translational Andrology and Urology concluded that oral testosterone undecanoate avoids first-pass hepatotoxicity through lymphatic absorption, a pharmacokinetic property that distinguishes it from older oral methyltestosterone formulations and supports use in patients with injection barriers [10].

Medicaid hearing officers are administrative law judges, not clinicians. The argument that works is not "this drug is better." The argument that works is "the denial contradicts the published criteria in your own PDL and the physician documented exactly what those criteria require."

Jatenzo Costs Without Medicaid Coverage

If Medicaid denies Jatenzo and appeals fail, patients face the list price directly. The average wholesale price runs approximately $900 per month, making it one of the more expensive testosterone formulations on the market. No generic oral testosterone undecanoate is currently FDA-approved in the United States, so therapeutic substitution within the same drug class is not an option.

Alternatives worth discussing with a prescriber include: testosterone cypionate injection (generic, often $30 to $50 per month at most pharmacies); testosterone enanthate injection (generic, similar pricing); testosterone 1.62% gel (generic available, approximately $100 to $200 per month depending on pharmacy); and testosterone pellets (buprenorphine insertion procedure typically $300 to $600 per 3 to 6 months, coverage variable). Each formulation delivers testosterone but differs in pharmacokinetics, administration burden, and patient preference [11].

The FDA maintains a list of approved testosterone products with labeling documents accessible through the Drugs@FDA database, which prescribers can use to verify that a substituted product carries the same indication as Jatenzo before documenting a therapeutic alternative in a Medicaid PA request [12].

For patients in managed care Medicaid plans, the plan's formulary exception process (distinct from the state fair hearing) may allow a non-formulary drug to be covered at a preferred cost-sharing level when medical necessity is documented. This exception pathway bypasses step therapy entirely in states with step-therapy exception laws, provided the prescriber can show that the preferred alternatives are clinically contraindicated.

Manufacturer Savings Cards and Medicaid: A Hard Stop

The Clarus Therapeutics patient savings program for Jatenzo cannot be used by patients enrolled in any federal or state government health insurance program, including Medicaid, Medicare, and TRICARE. This prohibition is not a company policy choice. It reflects federal anti-kickback statute requirements codified at 42 U.S.C. Section 1320a-7b(b), which prohibit pharmaceutical manufacturers from providing inducements that reduce a beneficiary's cost-sharing obligation under a government program [13].

Patients who use a manufacturer coupon while enrolled in Medicaid risk triggering a false-claims investigation, and pharmacies that accept such coupons for Medicaid patients can face recoupment. The only legitimate manufacturer-assistance pathway for Medicaid patients is a formal patient-assistance program (PAP) that provides the drug free of charge to income-qualified patients who have exhausted coverage options, separate from any third-party payer transaction.

Clarus offers a PAP for uninsured and underinsured patients. Contact information is on the Jatenzo manufacturer website, and the prescriber's office can submit documentation of Medicaid denial to initiate the PAP application. Processing typically takes 2 to 4 weeks.

What Medicaid Managed Care Plans Do Differently

Most Medicaid beneficiaries are now enrolled in Medicaid managed care organizations (MCOs) rather than fee-for-service state Medicaid. An MCO is a private insurer paid a per-member per-month capitation rate by the state to manage benefits. MCOs have their own formularies, which may differ from the state PDL, and their own PA criteria, which may be more or less restrictive than state defaults.

This creates a two-layer coverage question: (1) does your state Medicaid program cover Jatenzo, and (2) does your specific MCO plan cover Jatenzo? The answers can differ. A state may list Jatenzo as covered with PA on the PDL while the MCO a patient is enrolled in classifies it as non-covered pending a formulary exception. CMS requires that MCOs cover all drugs in the same mandatory covered drug categories as fee-for-service Medicaid, but testosterone is not in a mandatory category, leaving MCOs discretion [14].

Calling the MCO's pharmacy benefits manager directly, before the PA is submitted, to confirm the formulary status and exact PA criteria for that plan is the single most time-efficient step a prescriber's office can take. Getting the criteria in writing or documented with a reference number protects against moving-target criteria during the appeal process.

Documenting Hypogonadism for a Successful Jatenzo PA

The quality of the medical record determines coverage outcomes more than any other single variable in the prior authorization process.

Every Medicaid PA reviewer for Jatenzo will look for four elements: confirmed low testosterone with proper collection technique, a named underlying etiology consistent with the FDA label, documented symptom burden, and absence of contraindications. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy provides specific guidance on measurement: "We recommend against making the diagnosis of androgen deficiency in men with acute or subacute illness" [3]. That statement matters because Medicaid reviewers are trained to look for confounding conditions that could suppress testosterone transiently.

Prolactin and LH/FSH measurements help establish etiology and satisfy several states' PA requirements for secondary hypogonadism. Bone density (DXA scan) results, when available, add objective evidence of clinical consequences and strengthen both the initial PA and any appeal. A 2020 analysis in the Journal of Bone and Mineral Research found that men with hypogonadism had significantly lower lumbar spine BMD compared to eugonadal controls (mean difference 0.08 g/cm2, P<0.001), supporting the use of bone density data in clinical documentation [15].

The prescriber note submitted with the PA should directly mirror the payer's stated criteria, using the payer's language where possible. If the criteria document says "serum total testosterone <300 ng/dL on two morning fasting specimens," the note should say exactly that, not "low testosterone levels on labs." Payers match language; reviewers who cannot quickly find the matching phrase in a note often deny and move on.